Primary Care Clinics in Lovell, WY Accepting Medicare
4 Primary Care Clinics found. Showing 1 - 4
 One Health Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 229 E Main St, Lovell, WY 82431 Phone: 307-764-1602 |
Hoffman Snyder Tlc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 229 E Main St, Lovell, WY 82431 Phone: 307-548-9123 Fax: 307-548-9124 |
Strong Tree Clinic Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 342 E Main St, Lovell, WY 82431 Phone: 307-548-6289 Fax: 307-548-6910 |
North Big Horn Hospital Clinic Clinic/Center - Rural Health Medicare: Medicare Enrolled Practice Location: 1115 Lane 12, Lovell, WY 82431 Phone: 307-548-5201 Fax: 307-548-5224 |
News Archive
Nasogastric tube after abdominal surgery slows recovery
Routine use of a nasogastric tube after abdominal surgery, once thought to speed the return of normal intestinal functions, actually slows recovery, according to a new review of research.
Prostate cancer: Drug-resistant, metastasis-causing cells can produce exponentially growing tumors
The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.
Survival rates higher for children receiving living donor liver transplant
Children who undergo liver transplantation have better survival rates with living donor liver transplant graft than with deceased donor organ transplant, although factors other than the type of graft also are important, according to a study in the May issue of Archives of Surgery.
Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer
Medivation, Inc. has announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients.
New targets for Leishmaniasis
A comparison of three parasite species that cause Leishmaniasis has identified a small number of genes, many new to biology, that will provide a framework to target the search for new treatments.
› Verified 5 days ago